Immunization

Onymos Partners with the University of Cincinnati to Develop Innovative Document Conversion and Data Validation Tool

Retrieved on: 
Thursday, October 19, 2023
Internet of things, Digital, OCR, Smartphone, Health, Assistant, Physician, Organization, University, Student, Partnership, Space Applications Services, Immunization, Nursing, SAN, Integrated Data Store, Logic, Management, Salesforce

SAN FRANCISCO, Oct. 19, 2023 /PRNewswire/ -- Onymos, developer of the world's first Features-as-a-Service platform, today announced its newest customer, the University of Cincinnati. The goal of this partnership was to enable the University of Cincinnati to create an innovative new tool that will enable the rapid, accurate, and secure conversion, validation, and entry of healthcare data from thousands of students. This will ultimately provide the university's healthcare staff with even more time to focus on student health and wellness rather than paperwork.

Key Points: 
  • The goal of this partnership was to enable the University of Cincinnati to create an innovative new tool that will enable the rapid, accurate, and secure conversion, validation, and entry of healthcare data from thousands of students.
  • Additionally, manual data entry is known to generate errors that can go unnoticed in healthcare data and record systems.
  • "We are honored to have the opportunity to work with the University of Cincinnati to develop their application through our Features-as-a-Service platform."
  • For more information on Onymos, its Features-as-a-Service platform, DocKnow, or how it can help your education institution, visit Onymos.com .

DHSS launches interactive statewide flu dashboard

Retrieved on: 
Friday, October 13, 2023
Missouri Department of Health and Senior Services, Health, COVID-19, Antibody, Advisory Committee on Immunization Practices, Food, Death, Vaccine, Cough, Influenza-like illness, Food and Drug Administration, Hospital, Advisory Committee, Immunization, CDC, Safety, Season, Missouri Department of Social Services, Education, Vaccination, DHSS, Virus, Data, Fever, Infection, Influenza, RSV, Patient, Management, The Missourians

It is available as an interactive online dashboard , launched today.

Key Points: 
  • It is available as an interactive online dashboard , launched today.
  • The first week of this official flu season, Oct. 1-7, showed low flu activity with 125 laboratory-confirmed cases of influenza A and B reported statewide.
  • The dashboard streamlines the previous weekly flu reports , which DHSS has produced for many years during each official flu season (October through mid-May).
  • “This dashboard is another example of our continued commitment to modernizing the data we collect, analyze and share with Missourians,” said DHSS Director Paula F. Nickelson.

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Retrieved on: 
Monday, October 9, 2023
Patent, Infection, Matrix (biology), Cancer, COVID-19, GeoVax, Death, Vaccine, Weight loss, Intellectual property, Survival, Biotechnology, MVA, FDA, Vaccination, Immunization, Virus-like particle, VP40, Viremia

ATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No.

Key Points: 
  • ATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No.
  • A recent presentation of data from nonhuman primate studies demonstrated that immunization with GeoVax’s vaccine candidate, GEO-MM01, conferred 80% survival in cynomolgus macaques following a lethal dose of Marburg virus.
  • GeoVax is currently evaluating study designs to assess the potential for administering different dose levels of the vaccine and different routes of vaccine delivery to optimize utility and efficacy.
  • This patent allowance adds to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, now standing at over 115 granted or pending patent applications spread over 24 patent families.”

Pro football players team up for 'Punts for Purpose' on behalf of Compassion International

Retrieved on: 
Friday, October 13, 2023
Commander, Malnutrition, Mercedes-Benz Stadium, Infant, Tress Way, Compassion, Pinion, Way, Compassion International, Punt, Atlanta Falcons, Mortality, Prenatal care, 2016 Atlanta Falcons season, Hunger, Education, Poverty, Washington Commanders, Immunization, Mother, Corey Bojorquez, Bradley Pinion, Child, Athlete, Cleveland Browns, Falcon, Holiday, Surveying, Birth control

COLORADO SPRINGS, Colo., Oct. 13, 2023 /PRNewswire/ -- This Sunday, the Washington Commanders face the Atlanta Falcons at Mercedes-Benz Stadium. However, as opposing punters Bradley Pinion, Falcons, and Tress Way, Commanders, approach game day, they'll be punting for a bigger purpose. For each punt that lands inside the 20-yard line, both Pinion and Way have committed to donate $1,000 to child development organization Compassion International to fight poverty in an initiative called "Punts for Purpose."

Key Points: 
  • However, as opposing punters Bradley Pinion, Falcons, and Tress Way, Commanders, approach game day, they'll be punting for a bigger purpose.
  • And approximately 99 percent of maternal and 90 percent of neonatal mortalities occur in the developing world.
  • Ashleigh Alcorn, manager of pro athlete partnerships at Compassion, expressed, "Compassion loves partnering with pro athletes to bring attention to children living in abject poverty.
  • We're also all on Team God – the only team that truly matters."

Combined Therapeutics CEO, Romain Micol, to Present at the World Vaccine Congress Europe 2023

Retrieved on: 
Wednesday, October 11, 2023
Congress, UTR, CTX, RNA, Cell, Immunity, Therapy, Liver, MicroRNA, MPH, Heart, Safety, Biotechnology, CEST, Combined, Immunization, Tissue, Messenger, NHP, Pharmaceutical industry, Vaccine

BOSTON, Oct. 11, 2023 /PRNewswire/ -- Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA vaccines and therapeutics with a novel modified-mRNA platform to treat and prevent infectious diseases and cancer, today announced the participation of Romain Micol, M.D., MPH, Ph.D., President and CEO of Combined Therapeutics, as a speaker at the World Vaccine Congress Europe 2023, taking place from October 17 to 19 in Barcelona, Spain.

Key Points: 
  • "We are elated to share our findings at the World Vaccine Congress Europe 2023 and to discuss our progress toward developing the next generation of mRNA vaccines," said Dr. Romain Micol, CEO of Combined Therapeutics.
  • "Our MOPCTx mRNA platform has demonstrated exceptional promise in preclinical studies, showcasing an enhanced biodistribution profile, improved organ protection, and no compromise in vaccine efficacy.
  • Its precision in targeting therapeutic protein expression while simultaneously safeguarding vital organs represents an important advancement in our field."
  • Proof of concept studies in non-human primates (NHPs) confirmed the efficacy of the MOPCTx platform in decreasing overall systemic vaccine antigen expression after intramuscular immunization.

New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

Retrieved on: 
Wednesday, October 11, 2023
Incidence, Health, COVID-19, Public, ASX, CSL, Outcome, Death, Season, Influenza, Vaccination, Person, Immunization, ICU, Vaccine

The data highlights the effectiveness and value of influenza vaccination in the U.S. across all relevant age groups, risk profiles, and influenza seasons with different levels of influenza burden.1,2,3 These analyses will be presented during poster sessions this week at the IDWeek 2023 conference taking place in Boston, Mass.

Key Points: 
  • The data highlights the effectiveness and value of influenza vaccination in the U.S. across all relevant age groups, risk profiles, and influenza seasons with different levels of influenza burden.1,2,3 These analyses will be presented during poster sessions this week at the IDWeek 2023 conference taking place in Boston, Mass.
  • from October 11-15, 2023.
  • "Observing an ever-growing set of real-world outcomes is critical to ensuring that cell-based influenza vaccine technology continues to push public health forward."
  • "With the 2023/24 Northern Hemisphere influenza season underway, we're committed to working with our partners in public health to help demonstrate the importance of vaccination for our communities and health systems, particularly following a significant drop in flu immunization rates since the COVID-19 pandemic."

ApiJect Systems, Corp. Bolsters Global Health Team with Esteemed Anthropologist and Leading Expert on Vaccine Hesitancy, Dr. Heidi J. Larson, as Senior Advisor

Retrieved on: 
Wednesday, October 4, 2023
Communication, Risk, Stuck: How Vaccine Rumors Start and Why They Don't Go Away, University, Institute for Health Metrics and Evaluation, BBC, Health education, University of Washington, World Health Organization's response to the COVID-19 pandemic, COVID-19, Senior advisor, ApiJect Systems, Research, Vaccine hesitancy, Doctor of Philosophy, Theory, UNICEF, Thought, Vaccine Confidence Project, Patient, Evaluation, Platform, Tropical medicine, Global North and Global South, Hygiene, Health, Immunization, Woman, Clinical, London School of Hygiene and Tropical Medicine, Management, Vaccine, Anthropology

Dr. Larson is best known for groundbreaking research that advances the medical, scientific, social, and political understanding of vaccine hesitancy.

Key Points: 
  • Dr. Larson is best known for groundbreaking research that advances the medical, scientific, social, and political understanding of vaccine hesitancy.
  • She has engaged in effective advocacy for better health education and policies by building consensus and critical partnerships that influence health interventions and shape policies.
  • She is the Founder and Director of The Vaccine Confidence Project, which since 2010 has worked throughout the world to overcome vaccine hesitancy.
  • She has published extensively on the topic, including her book, STUCK: How Vaccine Rumors Start—and Why They Don't Go Away.

Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Pharmaceutical, Teens, Health, Children, Infectious Diseases, Consumer, Clinical Trials, Vaccine, Immunization, Communication, VE, SAGE, Dengue fever, Hospital, Public, Feedback, TAK, Infection, Overalls, Fever, Person, Incidence, Fever Dream, Risk, VCD, Ageing, WHO, Safety, Disease, Takeda

Takeda ( TSE:4502/NYSE:TAK ) today announced that the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization shared recommendations for use of QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003).

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization shared recommendations for use of QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003).
  • SAGE made the following recommendations:
    The vaccine to be considered for introduction in settings with high dengue disease burden and high transmission intensity to maximize the public health impact and minimize any potential risk in seronegative persons.
  • The vaccine to be introduced to children aged 6 to 16 years of age.
  • Within this age range, the vaccine should be introduced about 1-2 years prior to the age-specific peak incidence of dengue-related hospitalizations.

How to Make a Difference This Halloween

Retrieved on: 
Monday, October 2, 2023
Diamond, Education, Survival, UNICEF, Movement, Candy, Halloween, Sanitation, Child, UNICEF USA, Microsoft family features, Horn, Immunization, Social media, Entertainment

This year, you can make Halloween more than just a festive holiday by making a difference for children worldwide.

Key Points: 
  • This year, you can make Halloween more than just a festive holiday by making a difference for children worldwide.
  • Donations to the Trick-or-Treat for UNICEF campaign raise critical funds and relief for children where and when they need it most.
  • "Trick-or-Treat for UNICEF is a beloved Halloween tradition celebrated over the last 73 years by families all across America, mine included," said Shelley Diamond, chief marketing officer at UNICEF USA.
  • "This year, we thought outside the renowned, 'little orange box' and are thrilled to introduce the 'click-or-treat' virtual experience.

FMWC HPV Task Force Issues New White Paper to Address Ongoing HPV Vaccination Crisis in Ontario

Retrieved on: 
Sunday, October 1, 2023
Vaccine, Communication, Public Health Ontario, Vaccination, Accidental Death and Disability: The Neglected Disease of Modern Society, White paper, Public, Parent, COVID-19, Head, Medical Women's Federation, Research, Neck, Government, School, Dentist, Student, Pharmacist, Federation, Anal cancer, Patient, Cervical cancer, Physician, Risk, FMWC, Disability-adjusted life year, Fire Prevention Week, HPV, Immunization

The White Paper offers 10 essential recommendations for health care providers, Public Health Ontario and the Ontario Ministry of Health aimed at recovering pre-pandemic school-led immunization levels in the province and addressing the barriers to reaching Canada's 90 percent HPV immunization coverage commitment.

Key Points: 
  • The White Paper offers 10 essential recommendations for health care providers, Public Health Ontario and the Ontario Ministry of Health aimed at recovering pre-pandemic school-led immunization levels in the province and addressing the barriers to reaching Canada's 90 percent HPV immunization coverage commitment.
  • The White Paper produced by the task force calls on the provincial government to immediately work towards implementing a unified provincial vaccine registry as a primary goal.
  • All together, the 10 essential recommendations outlined in the White Paper aim to increase HPV vaccine awareness among key groups and improve deficiencies in communication, collaboration, technology and access.
  • For more details on the FMWC White Paper and its recommendations, please visit canadavshpv.ca .